State of New Jersey Common Pension Fund D Has $2.67 Million Stock Holdings in TG Therapeutics, Inc. $TGTX

State of New Jersey Common Pension Fund D boosted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 34.4% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 73,933 shares of the biopharmaceutical company’s stock after buying an additional 18,926 shares during the period. State of New Jersey Common Pension Fund D’s holdings in TG Therapeutics were worth $2,671,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of TGTX. Johnson Financial Group Inc. acquired a new position in shares of TG Therapeutics in the second quarter valued at approximately $25,000. Bessemer Group Inc. boosted its stake in TG Therapeutics by 117.1% in the 3rd quarter. Bessemer Group Inc. now owns 901 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 486 shares during the period. Salomon & Ludwin LLC acquired a new position in TG Therapeutics in the 3rd quarter valued at $34,000. Stone House Investment Management LLC bought a new position in TG Therapeutics during the 3rd quarter worth $36,000. Finally, EverSource Wealth Advisors LLC lifted its holdings in shares of TG Therapeutics by 86.3% during the second quarter. EverSource Wealth Advisors LLC now owns 1,237 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 573 shares in the last quarter. 58.58% of the stock is owned by institutional investors.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $32.57, for a total value of $162,850.00. Following the sale, the director directly owned 223,816 shares in the company, valued at approximately $7,289,687.12. This trade represents a 2.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 10.64% of the company’s stock.

TG Therapeutics Trading Up 0.2%

Shares of TGTX stock opened at $29.53 on Friday. TG Therapeutics, Inc. has a fifty-two week low of $25.28 and a fifty-two week high of $46.48. The stock’s fifty day moving average price is $29.90 and its two-hundred day moving average price is $31.34. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.89 and a current ratio of 3.82. The company has a market cap of $4.69 billion, a PE ratio of 10.62 and a beta of 1.85.

Analyst Ratings Changes

Several research firms recently commented on TGTX. Wall Street Zen downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of TG Therapeutics in a report on Wednesday, January 14th. The Goldman Sachs Group lifted their price target on shares of TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th. Finally, JPMorgan Chase & Co. reduced their price target on TG Therapeutics from $49.00 to $46.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $50.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.